36220-29-8

Usage

InChI:InChI=1/C9H11ClO2/c1-7-6-8(10)2-3-9(7)12-5-4-11/h2-3,6,11H,4-5H2,1H3

Upstream product

• 75-21-8 oxirane 
• 1570-64-5 2-methyl-4-chlorophenol 
• 107-07-3 2-chloro-ethanol 
• 6161-86-0 2-methylphenoxyethanol 
• 540-51-2 2-bromoethanol 

Downstream Products

• 100120-21-6 1-(4-chloro-2-methyl-phenoxy)-2-(2,2-dichloro-propionyloxy)-ethane 
• 119015-89-3 dichlorophosphoric acid-[2-(4-chloro-2-methyl-phenoxy)-ethyl ester] 
• 99984-24-4 1-(4-chloro-2-methyl-phenoxy)-2-trichloroacetoxy-ethane 
• 3653-48-3 sodium 2-methyl-4-chlorophenoxyacetate 
• 1254734-39-8 R,S-2-[(4-chloro-2-methylphenoxy)ethyl]amino-1-phenylethan-1-ol 
• 26378-21-2 (4-chloro-2-methylphenoxy)ethyl bromide 
• 1254734-34-3 R,S-1-[(4-chloro-2-methylphenoxy)ethyl]aminopropan-2-ol 
• 1254734-35-4 R,S-2-[(4-chloro-2-methylphenoxy)ethyl]aminopropan-1-ol 
• 1254734-36-5 R,S-1-[(4-chloro-2-methylphenoxy)ethyl]aminobutan-2-ol 
• 1254734-37-6 R,S-2-[(4-chloro-2-methylphenoxy)ethyl]aminobutan-1-ol 
• 1254734-38-7 2-[(4-chloro-2-methylphenoxy)ethyl]amino-2-methylpropan-1-ol 
• 94-74-6 MCPA 

Relevant academic research and scientific papers

PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

A method for preparing chloro-benzene oxygen carboxylic acid (by machine translation)

The invention provides a method for preparing carboxylic acid chloro-benzene oxygen, comprising the following steps: S1) phenoxy fatty alcohol in the catalyst B A and under the action of the catalyst, and the chlorinating agent to 2 bit and/or 4 bit selective chlorination reaction, to obtain chloro-benzene oxygen fatty alcohol; said catalyst A is Lewis acid; said catalyst B is C5 - 22 of the thioether, thiazole, isothiazole, thiophene or their halogenated derivatives; S2) [...] fatty alcohol and water, under the action of a catalyst, and an oxidizing agent for the selective catalytic oxidation reaction, get chloro-benzene oxygen carboxylic acid. The invention through the re-design of the process route, the catalyst and the chlorinating agent fine screening, effectively reduces the energy consumption, the selectivity of the dichloride to improve at the same time avoiding the losses of the active ingredient, the resulting chloro-benzene oxygen carboxylic acid content can be up to 98.5% or more, the total yield can be up to 99% or more. (by machine translation)

Synthesis and evaluation of anticonvulsant activity of some N-[(4-Chlor-2-methylphenoxy)ethyl]- and N-[(4-Chlor-2-methylphenoxy)acetyl] aminoalkanols

A new series of N-(4-chlor-2-methylphenoxy)ethyl- (1-6) and N-(4-chlor-2-methylphenoxy)acetylaminoalkanols (7-10) has been synthesized for evaluation of their anticonvulsant activity. Pharmacological tests included maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole seizure (ScMet) assays, as well as rotarod for neurotoxicity (TOX) and were performed in mice i.p. and rats p.o. The activity of the compounds in the group was various, and the most active compound in mice was R,S-1N-[(4-chlor-2-methylphenoxy) ethyl]aminopropan-2-ol, revealing 100% activity in MES test at 30 mg/kg b.w., 0.5 h after administration without toxicity at the same dose and time. In rats (p.o.), the most active compound was 2N-[(4-chlor-2-methylphenoxy)ethyl]amino-2- methylpropan-1-ol, revealing 25% activity in MES at 30 mg/kg b.w. 0.5 and 1 h after administration.